Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms

Halliday, Glenda, Robinson, Stephen R, Shepherd, Claire, Kril, Jillian · 2000 · Clinical and Experimental Pharmacology and Physiology

Abstract

SUMMARY: 1. Of the neurodegenerative diseases that cause dementia, Alzheimer’s disease (AD) is the most common. Three major pathologies characterize the disease: senile plaques, neurofibrillary tangles and inflammation. We review the literature on events contributing to the inflammation and the treatments thought to target this pathology. 2. The senile plaques of AD consist primarily of complexes of the β‐amyloid protein. This protein is central to the pathogenesis of the disease. 3. Inflammatory microglia are consistently associated with senile plaques in AD, although the classic inflammatory response (immunoglobulin and leucocyte infiltration) is absent. β‐Amyloid fragments appear to mediate such inflammatory mechanisms by activating the complement pathway in a similar fashion to immunoglobulin. 4. Epidemiological studies have identified a reduced risk of AD in patients with arthritis and in leprosy patients treated with anti‐inflammatory drugs. Longitudinal studies have shown that the consumption of anti‐inflammatory medications reduces the risk of AD only in younger patients (< 75 years). 5. There is a considerable body of in vitro evidence indicating that the inflammatory response of microglial cells is reduced by non‐steroidal anti‐inflammatory drugs (NSAID). However, no published data are available concerning the effects of these medications on brain pathology in AD. 6. Cyclo‐oxygenase 2 enzyme is constitutively expressed in neurons and is up‐regulated in degenerative brain regions in AD. Non‐steroidal anti‐inflammatory drugs may reduce this expression. 7. Platelets are a source of β‐amyloid and increased platelet activation and increased circulating β‐amyloid have been identified in AD. Anti‐platelet medication (including NSAID) would prevent such activation and its potentially harmful consequences. 8. Increased levels of luminal β‐amyloid permeabilizes the blood–brain barrier (BBB) and increases vasoconstriction of arterial vessels, paralleling the alterations observed with infection and inflammation. Cerebral amyloidosis is highly prevalent in AD, compromising the BBB and vasoactivity. Anti‐inflammatory medications may alleviate these problems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1440-1681.2000.03200.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 208

Metadata

Authors
Halliday, G., Robinson, S. R., Shepherd, C., & Kril, J.
Venue
Clinical and Experimental Pharmacology and Physiology
Publisher
Wiley
Published
2000-01-04
Volume
27
Issue
1-2
Pages
1-8
ISSN
  • 0305-1870 (ISSN-L)
  • 1440-1681
OpenAlex
W1996223952
Cited by
208
References
12
FWCI
10.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. https://app.cochat.ai/papers/10.1046/j.1440-1681.2000.03200.x
The paper
Halliday, G., Robinson, S. R., Shepherd, C., & Kril, J. (2000). Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1046/j.1440-1681.2000.03200.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.